OnCo

No description yet: the sentence for this tag has not been written. 2 records carry it: 2 biomarkers.

Related tags
2 records
FGFR2 fusion or rearrangement
FGFR2
FGFR2 fusions occur in 10 to 15 percent of intrahepatic bile duct cancers and almost nowhere else. Pemigatinib and futibatinib are approved for them after a first chemotherapy.
FGFR3 alteration (mutation or fusion)
FGFR3
FGFR3 point mutations and TACC3 fusions drive about 15 to 20 percent of advanced bladder cancers. Erdafitinib is approved for tumours with these 'susceptible' alterations after one prior treatment.

This tag as JSON · API